Genelux is a clinical-stage biopharmaceutical company developing an oncolytic virus-based technology platform and a pipeline of products with applications for cancer detection and therapy. Its oncology product candidate, GL-ONC1, is an attenuated vaccina virus that results in regression and elimination of a range of solid tumors in animals without damaging healthy tissues or organs.